Sponsor Preference of CRO Experience in Orphan Drug Trials
Despite the substantial difficulties associated with orphan drug trial recruitment, this segment of the drug development market is booming. By 2020, orphan drug sales are expected to make up 19% of prescription drug sales, excluding generics. In ISR’s Orphan Drug Market Dynamics and Patient Recruitment Best Practices report, ISR provides an overview of the orphan drug development market as well as how to best drive patient recruitment in an area of drug development in which drug developers do not want to be left behind. Read more here.
Source: Industry Standard Research, February 2015
Source: Industry Standard Research, February 2015
Source: Industry Standard Research, February 2015
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
